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Objectives. We sought to evaluate the risk of thromboembolic
events in the presence of chronic atrial flutter and to determine
the impact of anticoagulation therapy, if any, on this risk.
Background. Thromboembolic events are thought to be rare
after cardioversion of atrial flutter.
Methods. This study was a retrospective analysis of 110 con-
secutive patients referred to the electrophysiology laboratory for
cardioversion of chronic atrial flutter from 1986 to 1996. Atrial
flutter was present for at least 6 months. Of the 110 patients
reviewed, 100 had adequate information available regarding the
effectiveness of anticoagulation (mean age 64 years, range 27 to
86; 75 men, 25 women; mean left ventricular ejection fraction
42%).
Results. Thirteen patients (13%) had a thromboembolic event.
Of these, seven were attributable to causes other than atrial
flutter. In the remaining six patients (6%), thromboembolic events
occurred during a rhythm of atrial flutter or after cardioversion to
sinus rhythm. Other causes of thromboembolism were excluded.
Effective anticoagulation was associated with a decreased risk of
thromboembolism (p 5 0.026).
Conclusions. Patients with chronic atrial flutter are at an
increased risk of thromboembolic events. Effective anticoagula-
tion may decrease this risk.
(J Am Coll Cardiol 1997;30:1506–11)
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Atrial flutter was first described almost 90 years ago. It is a
frequently observed cardiac arrhythmia, almost as common as
all other regular supraventricular tachycardias combined (1).
Of those patients admitted with a diagnosis of supraventricular
tachycardia between 1985 and 1990, 77% had atrial fibrillation
and 10% had atrial flutter (2). In 1990, 21,000 patients were
discharged with a primary diagnosis of atrial flutter, whereas
86,000 patients had atrial flutter as one of seven discharge
diagnoses (3).
Atrial flutter is usually symptomatic, with the most common
symptom being palpitations. It is often less well tolerated than
atrial fibrillation (4). This may be due to the abrupt, striking
increase in the ventricular response rate that can occur with
little physical exertion with atrial flutter. Atrial flutter may
cause hypotension, angina or congestive heart failure depend-
ing on the ventricular response rate, persistence of the atrial
flutter and underlying ventricular function. After return to
sinus rhythm, immediate improvement in symptoms and ven-
tricular function are possible (5,6). Tachycardia-mediated car-
diomyopathy, which can result from chronic atrial flutter, may
completely resolve over time (7–9). Cardioversion is therefore
often recommended.
After cardioversion of atrial flutter, thromboembolic events
are thought to be rare and are less likely to occur than after
cardioversion of atrial fibrillation. Anticoagulation has there-
fore been considered unnecessary (10). Surprisingly, the true
risk of clinically apparent thromboembolic events occurring in
patients with chronic atrial flutter has not been addressed
carefully. The major clinical trials of anticoagulation therapy
for atrial fibrillation excluded patients with atrial flutter (11–
16). In several small published trials of cardioversion, patients
with atrial fibrillation, atrial flutter and supraventricular tachy-
cardias were pooled for analysis (17–20), making interpreta-
tion difficult.
To further evaluate the risk of thromboembolic events in
the presence of chronic atrial flutter, we retrospectively re-
viewed the results of all patients referred to the electrophysi-
ology laboratory for cardioversion of chronic atrial flutter from
1986 to 1996.
Methods
Patients. This study was a retrospective analysis of 110
consecutive patients referred to the electrophysiology labora-
tory for cardioversion of chronic atrial flutter from January
1986 through May 1996. Of the 110 patients reviewed, 100 had
adequate information available regarding the effectiveness of
anticoagulation, documented persistence of atrial flutter and
underlying heart disease to be included in the study. Twenty-
eight patients had a history of cardioversion before referral.
All patients included were successfully converted to normal
sinus rhythm with either overdrive right atrial pacing (16%) or
direct current cardioversion (84%). Thirty-six patients under-
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went repeat cardioversion for recurrent atrial flutter during the
study period. Atrial flutter was the predominant rhythm for a
minimal duration of 6 months, but was present up to 5 years
before presentation. Sixty-five patients had coronary artery
disease (CAD); 17 patients had valvular heart disease; 10
patients had other forms of heart disease; and 10 patients had
no structural heart disease. The mean left ventricular ejection
fraction was 42%.
Study protocol. Definition of cardiac rhythm. Atrial flutter
was defined as an organized atrial tachycardia at a rate of $240
beats/min. Using established criteria, atrial flutter was diag-
nosed by the 12-lead electrocardiogram (ECG) in all patients
included in this study (4,21,22).
Definition of effectiveness. Anticoagulation was considered
effective if the international normalized ratio (INR) was $2.0
and the prothrombin time (PT) was $16 s consistently. Deter-
mination of the effectiveness of anticoagulation was made
based on all PT/INR values obtained in the 4 weeks before
cardioversion. Any subtherapeutic values obtained during this
time placed the patient in the ineffectively anticoagulated
group. In the case of spontaneous thromboembolism, the last
PT/INR value obtained before presentation, as well as the
PT/INR value obtained immediately after the events, was
evaluated in a similar manner. Some patients considered to be
effectively anticoagulated before cardioversion had episodes of
ineffective anticoagulation at times other than those specified
previously. Some patients were not anticoagulated at all. These
patients were included in the group of ineffectively anticoagu-
lated patients for the purpose of this study.
Thromboembolic events. The determination of a thrombo-
embolic event was based on clinical findings and supported by
radiologic studies, including a computerized axial tomographic
scan of the head and cerebral angiography. All patients who
experienced a thromboembolic event underwent a screening
two-dimensional echocardiogram and carotid Doppler studies,
as is the usual practice in our institution.
Data collection. Various clinical variables were assessed,
including age, gender, anticoagulation status, presence and
type of heart disease, ejection fraction, history of hypertension
(HTN), history of diabetes, previous cardioversion, episodes of
transient atrial fibrillation and thromboembolic events. Clini-
cal examination, diagnostic evaluation and the results of
pertinent tests performed after any thromboembolic events
were also noted. Persistence of flutter was documented by
evaluation during patient examinations, ECG recordings and
patient history. Episodes of transient atrial fibrillation were
documented by ECG or Holter recordings. No long-term
rhythm monitoring was performed in any patient involved in
the study.
Statistical analysis. Data were analyzed using the two-
tailed Fisher exact test. Patients who had effective anticoagu-
lation were compared for risk of thromboembolism with those
who had ineffective anticoagulation using the definitions pre-
viously described.
Results
One hundred patients were studied; fifty four received
effective anticoagulation; 30 had ineffective anticoagulation;
and 16 had no anticoagulation before cardioversion or the
thromboembolic event, or both.
Patients were grouped by anticoagulation status into two
subgroups. The first group included patients with effective
anticoagulation before cardioversion or the thromboembolic
event, or both. The second group included patients with either
ineffective or no anticoagulation before cardioversion or the
thromboembolic event, or both. A comparison of the baseline
characteristics of the patients in the effective, ineffective and
no anticoagulation groups are presented in Table 1. These
groups were similar with respect to age, gender, left ventricular
ejection fraction and history of HTN. Notably, the groups
differed with respect to the presence and type of cardiac
disease. More patients with valvular heart disease received
effective anticoagulation; more patients without heart disease
had ineffective or no anticoagulation. The implications of this
disparity are addressed subsequently. Four patients from the
effective anticoagulation group and two from the ineffective or
no anticoagulation group had transient atrial fibrillation de-
tected during the study period.
Thromboembolic events. Thirteen patients experienced a
thromboembolic event during the study. Effective anticoagula-
Abbreviations and Acronyms
CAD 5 coronary artery disease
CVA 5 cerebrovascular accident
ECG 5 electrocardiogram, electrocardiographic
HTN 5 hypertension
INR 5 international normalized ratio
PT 5 prothrombin time
Table 1. Baseline Characteristics of Patients According to
Anticoagulation Status
Ineffective or
No Anticoagulation
(n 5 46)
Effective
Anticoagulation
(n 5 54)
Mean age (yr) 64 63.6
Range 27–86 37–82
Men/women 35/11 40/14
LV ejection fraction 43% 41%
Coronary heart disease 32 (69%) 33 (61%)
Valvular heart disease 1 (,1%) 16 (29%)
Other heart disease* 4 (9%) 6 (11%)
No heart disease 7 (15%) 3 (6%)
Hypertension 21 (21%) 21 (46%)
Diabetes 15 (28%) 12 (26%)
Previous cardioversion 15 (32%) 13 (24%)
Transient atrial fibrillation 2 (4%) 4 (7%)
*Includes atrial septal defect (n 5 1), hypertrophic cardiomyopathy (n 5 2),
orthotopic heart transplantation (n 5 2), dilated cardiomyopathy (n 5 4) and
amyloid heart disease (n 5 1). Data presented are number (%) of patients,
unless otherwise indicated. LV 5 left ventricular.
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tion was associated with a significantly decreased risk of
thromboembolic events (p 5 0.026 by two-tailed Fisher exact
test). No thromboembolic events occurred in the 54 patients
who had effective anticoagulation (Table 2). Seven patients
had thromboembolic events that were probably not related to
atrial flutter (Table 3). In these patients, either the thrombo-
embolic events occurred before the onset of atrial flutter or
another likely source of embolism was detected.
Three patients developed clinical manifestations of a cere-
brovascular accident (CVA) before the documented onset of
atrial flutter. A fourth patient was found to have significant
carotid artery atherosclerotic disease documented by carotid
Doppler studies after a retinal artery embolus. A left ventric-
ular thrombus was detected on transthoracic echocardiography
after the thromboembolic event in the remaining three pa-
tients.
For the remaining six patients with clinically apparent
thromboembolic events, atrial flutter was considered the most
probable causal factor. In all cases, carotid Doppler studies
and transthoracic echocardiograms were unremarkable for a
source of emboli. All CVAs were verified by a computed
tomographic scan.
Patients with thromboembolic events attributed to atrial flut-
ter. PATIENT 1 was a 27-year old woman with hypertrophic
cardiomyopathy. Coumarin therapy was withheld before radio-
frequency catheter ablation of atrial flutter. Forty-eight hours
after successful ablation, the patient had a pulmonary embo-
lism verified by pulmonary angiography. Venographic studies
of the lower extremities revealed no evidence of thrombosis.
PATIENT 2 was an 84-year old woman without a history of
cardiac disease who developed two transient ischemic attacks
during a period of ineffective anticoagulation.
PATIENT 3 was a 68-year old woman with rheumatic heart
disease who had ineffective anticoagulation before cardiover-
sion of atrial flutter. The patient developed amaurosis fugax
24 h after cardioversion to sinus rhythm. An ophthalmologic
examination revealed a retinal artery thromboembolus.
PATIENT 4 was a 59-year old man without cardiac disease
who had no anticoagulation for chronic atrial flutter. The
patient had a right basal ganglia cerebral infarct within 48 h
after cardioversion to sinus rhythm.
PATIENT 5 was a 66-year old man with a history of ischemic
cardiomyopathy and chronic atrial flutter. The patient had a
right temporal lobe CVA during a period of ineffective anti-
coagulation.
PATIENT 6 was a 58-year old man with CAD, a left ventric-
ular ejection fraction of 35% and chronic atrial flutter. He had
a right occipital-temporal lobe CVA during a period of inef-
fective anticoagulation.
Discussion
On the basis of our findings, it appears that chronic atrial
flutter is associated with a remarkably high risk of clinically
apparent thromboembolism. Effective anticoagulation appears
to reduce this risk.
Considering the common occurrence of atrial flutter, sur-
prisingly little information is available to determine the true
risk of a thromboembolic event. As noted previously, the data
from most published studies have suggested that the incidence
of thromboembolism in atrial flutter is low (10–20).
Arnold et al. (23) reported no embolic events in 122
cardioversions of patients with atrial flutter, 26% of whom
received anticoagulation. It was suggested that patients with
atrial flutter do not need anticoagulation. The reason our
results differed from those of Arnold et al. may lie in the nature
of the groups studied. Our study included only patients with
Table 2. Relation of Thromboemboli to Anticoagulation
Anticoagulation Group
Thromboemboli
Attributed to AF*
[no. (%) of patients]
Ineffective or none (n 5 46) 6 (15%)
Effective (n 5 54) 0
*p 5 0.026 by two-tailed Fisher exact text. AF 5 atrial flutter.
Table 3. Thromboembolic Events Probably Not Related to Atrial Flutter
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7
Age (yr)/gender 74/M 64/M 67/M 71/M 60/M 71/M 54/M
LV ejection fraction 30% 26% 68% 20% 18% 25% 35%
Heart disease CAD CAD CAD CAD CAD CAD CAD
Hypertension No Yes Yes No No Yes Yes
Diabetes No No Yes No Yes No Yes
No. of cardioversions 1 3 0 0 0 0 0
Transient atrial fibrillation No No No Yes No No No
Near cardioversion No No No No No No No
Anticoagulation IE IE No IE IE No No
Other 1CD LVT * LVT LVT * *
Embolic event RAE CVA PE CVA CVA CVA MAE
*Clinical manifestion of embolic event preceded by atrial flutter. CAD 5 coronary artery disease; 1CD 5 significant
carotid artery stenosis detected by carotid Doppler studies; CVA 5 cerebrovascular accident; IE 5 ineffective
anticoagulation; LVT 5 left ventricular thrombus detected by echocardiography; MAE 5 mesenteric artery embolus;
PE 5 pulmonary embolism; RAE 5 retinal artery embolus.
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chronic atrial flutter and excluded those with recent onset
flutter and postoperative atrial flutter. In the study of Arnold
et al. (23), patients with postoperative fibrillation and flutter
represented the majority (67%) of the study group. Also, most
patients included in this study (73%) had acute or recent onset
of atrial arrhythmia, with a duration ,30 days. This difference
in etiology and duration of atrial flutter may be responsible for
the differences observed in the risk of thromboembolism
between the two studies. Patients with postoperative and acute
or recent onset atrial flutter may have a different and quite
possibly lower risk of thromboembolism than those with
chronic atrial flutter.
Chalasani et al. (24) reviewed 98 direct current cardiover-
sions of atrial flutter in 85 patients. Only 12% of the patients
had received anticoagulation before cardioversion. No throm-
boembolic events were reported up to 24 h after cardiover-
sion. It is unknown whether any patient developed thrombo-
embolic complications .24 h after cardioversion, as was
observed in two patients in our study. Also of note, the
duration of atrial flutter was unknown in 73 of 98 episodes
analyzed and was not reported in the remaining 25 episodes.
Thus, the applicability of this study to patients with chronic
atrial flutter is unknown.
Thromboembolic risk is thought to be low in atrial flutter
owing to the organized atrial contraction that may occur. This
synchronous activity is presumed to prevent blood stasis and
thrombus formation. Atrial function can be altered during
atrial flutter or after cardioversion to sinus rhythm, similar to
atrial fibrillation. Jordaens et al. (25) showed that atrial systolic
function can be diminished in atrial flutter and that the return
of atrial function can be delayed for days to weeks after
cardioversion. Atrial contribution to ventricular filling was
measured using echocardiographic Doppler-estimated dia-
stolic transmitral flow in 22 patients who were converted to
sinus rhythm using either direct current shock or rapid pacing.
Atrial contribution to ventricular filling was found to be
minimal or absent after conversion to sinus rhythm. Atrial
dysfunction lasted up to 2 weeks after cardioversion. As atrial
dysfunction occurred with either direct current cardioversion
or atrial pacing, “stunning” due to direct current cardioversion
did not appear to be the cause. Rather, atrial dysfunction
appeared to be due to the atrial flutter itself.
O’Neill et al. (26) found that the return of atrial mechanical
function after cardioversion is variable and often delayed. They
reported that a decrease in atrial mechanical function could
cause stasis of blood and formation of atrial thrombi.
Transesophageal echocardiography has greatly enhanced
the ability to identify patients with atrial arrhythmia who are
at greater risk of thromboembolism (27). Spontaneous echo-
cardiographic contrast medium (“smoke”) and left atrial ap-
pendage thrombi have been reported by transesophageal echo-
cardiographic studies in up to 35% of nonanticoagulated
patients with atrial flutter (28,29). Spontaneous echo contrast
medium, thought to represent stasis of blood in the atrium, has
been associated with an increased risk of thromboembolism
(30,31).
Another risk factor for thromboembolic events in patients
with chronic atrial flutter is the potential for transition, possi-
bly undiagnosed, between atrial fibrillation and atrial flutter.
Because atrial fibrillation has a well established risk of throm-
boembolism, conversion from flutter to fibrillation may
heighten the risk of thromboembolism. The alternation be-
tween atrial fibrillation and flutter may be asymptomatic and
can occur in up to 25% of patients with documented chronic
atrial flutter (32,33). Therefore, some investigators recom-
mend Holter monitoring of all patients with chronic atrial
flutter before cardioversion to exclude intermittent transitions
to atrial fibrillation (34).
Altered mechanical function of the atria and oscillation
between atrial flutter and fibrillation may explain the develop-
ment of atrial thromboemboli in patients with chronic atrial
flutter. The mechanisms responsible for thromboembolism in
chronic atrial flutter are, however, most likely multiple and
complex.
In our study, chronic atrial flutter was associated with a
substantial risk of thromboembolism, with 6 of 100 patients
developing a thromboembolic event attributed to atrial flutter.
This surprisingly high rate of thromboembolism has not been
previously reported in a large series of patients with atrial
flutter. No thromboembolic events were observed in the effec-
tively anticoagulated group. The fact that, at presentation of
thromboembolism, patients had subtherapeutic anticoagula-
tion or were not anticoagulated strongly supports a cause and
effect relation. This appears to confirm a protective benefit of
anticoagulation therapy in patients with chronic atrial flutter.
As noted previously, most of the patients with valvular heart
disease (16 of 17) had effective anticoagulation, whereas a
majority of those patients without underlying heart disease (7
of 10) received no anticoagulation. This noted disparity may be
a reflection of our clinical practice, which has been influenced
by previous reports (19,35) that have placed patients with
valvular heart disease and atrial arrhythmias at particularly
high risk for thromboembolism.
The task of determining the efficacy of anticoagulation
therapy is difficult. Most if not all patients with long-term
anticoagulation therapy have some periods of “subtherapeu-
tic” PT/INR values. Patients who experienced thromboembolic
events were placed in the ineffective anticoagulation group if
their PT/INR value was subtherapeutic at the time of presen-
tation. It is very possible that many patients considered to have
“effective anticoagulation” had undetected periods of ineffec-
tive anticoagulation not associated with an event. Because
these patients would have been considered to have “effective”
anticoagulation, our data would therefore underestimate inef-
fective anticoagulation. Even assuming this to be the case, an
overall high incidence of thromboembolism in patients with
chronic atrial flutter was noted in our study.
Our data are comparable to those of Wood et al. (36), who
reviewed 86 patients referred for radiofrequency catheter
ablation of chronic atrial flutter. In their report, 6 (7%) of 86
patients were found to have a history of thromboembolism
after cardioversion. The risk of thromboembolism in chronic
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atrial flutter may be underestimated and is likely much higher
than previously reported.
Study limitations. Our study was a nonrandomized, retro-
spective analysis of patients referred to a university hospital
electrophysiologic laboratory for treatment of chronic atrial
flutter. This is reflected in the high frequency of cardiac
disease, HTN and diabetes observed in this group. It is possible
that referral bias may have resulted in a patient group at
greater risk of thromboembolic complications than the “typi-
cal” patient group with atrial flutter.
Because the study was retrospective, the duration of anti-
coagulation, the frequency of PT/INR determination and the
therapeutic range “targeted” were determined by the referring
physicians caring for these patients. Our determination of the
efficacy of anticoagulation therapy was therefore limited by the
data available on individual patients.
The study is also limited by the ability of the investigators to
establish the source of thromboembolism. It is possible that the
actual cause of thromboembolism was undetected in the six
cases attributed to atrial flutter. As noted previously, it is not
uncommon for atrial flutter to convert spontaneously and
often symptomatically to atrial fibrillation. Alternatively, it is
possible that atrial flutter may have been the true source of
thromboembolism in any of the seven patients in whom
thromboembolism was attributed to other causes. In either
case, the incidence of thromboemboli in patients with chronic
atrial flutter who did not receive adequate anticoagulation is
high.
Conclusions. These data suggest that patients with chronic
atrial flutter are at a substantially increased risk of thrombo-
embolism. These thromboembolic events can occur after car-
dioversion to sinus rhythm or after spontaneous conversion to
either sinus rhythm or atrial fibrillation. Effective anticoagula-
tion was associated with a decreased risk of thromboembolism
in this study (p 5 0.026). We therefore recommend full
anticoagulation for chronic atrial flutter until large-scale, pro-
spective, randomized trials become available.
We thank Padmavathi Pagadala, MD for assistance.
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